Clinical Trial Detail

NCT ID NCT02535078
Title Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Cutaneous Melanoma
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Immunocore Ltd
Indications

skin melanoma

Therapies

Durvalumab

Tebentafusp

Tremelimumab

Age Groups: adult

No variant requirements are available.